Abstract
TA90 is a tumor-associated 90-kD glycoprotein antigen expressed on most melanoma cells, including those of CancerVax, a polyvalent allogeneic whole-cell vaccine. Previous studies have shown that a TA90 antigen-antibody immune complex (IC) in the serum of patients with melanoma is a marker of subclinical tumor burden and a strong prognostic factor. We hypothesized that the induction of TA90-IC during postoperative adjuvant CancerVax therapy might indicate vaccine-mediated immune destruction of subclinical melanoma cells with release of TA90, and thereby serve as a surrogate marker of vaccine efficacy. From 1993 to 1997, 219 melanoma patients were enrolled in a prospective phase II trial of CancerVax plus bacille Calmette-Guerin (BCG) after complete tumor resection. Coded serum samples were prospectively collected and analyzed for TA90-IC before and 2, 4, 8, 12, and 16 weeks after initiation of CancerVax therapy. TA90-IC seroconverters were those patients whose negative TA90-IC values (< .410) became positive (> or = .410) after initiation of CancerVax treatment. Before CancerVax therapy, 51 patients had positive TA90-IC values and 168 patients had negative TA90-IC values. During CancerVax treatment, all 51 positive patients rema...Continue Reading
References
Jan 1, 1992·Journal of Clinical Laboratory Analysis·R K Gupta, D L Morton
Oct 1, 1992·Annals of Surgery·D L MortonR Elashoff
Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·D M EuhusD L Morton
Jan 15, 1995·Cancer·A Barth, D L Morton
Nov 15, 1993·Cancer·M N SirottA N Houghton
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E TartourW H Fridman
Jul 1, 1996·CA: a Cancer Journal for Clinicians·D L Morton, A Barth
Sep 1, 1996·Annals of Surgical Oncology·R C JonesD L Morton
May 5, 1998·Cancer Letters·J ViacA Claudy
Sep 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E C HsuehD L Morton
Oct 8, 1998·Cancer·M C KelleyD L Morton
Citations
May 30, 2002·Annals of Surgery·Rebekah R WhiteHilliard F Seigler
May 3, 2014·Current Treatment Options in Oncology·Sarah A WeissAnna C Pavlick
Feb 20, 2016·Cancer Immunology, Immunotherapy : CII·Julia M GreeneGeorge E Peoples
May 19, 2012·Seminars in Oncology·Howard L Kaufman
Jan 8, 2010·Head & Neck·Walter T LeePeter Cohen
Jun 5, 2003·Technology in Cancer Research & Treatment·Margot Zöller
Aug 14, 2019·Applied Microbiology and Biotechnology·Martha Lucia Ruiz BenitezFabiana Kömmling Seixas
Apr 21, 2001·Annals of Surgical Oncology·H K LyerlyT M Clay
Dec 31, 2003·Annals of Surgical Oncology·Mark B FariesDonald L Morton
Jul 31, 2007·Cancer Investigation·Mark B FariesDonald L Morton
Jul 25, 2003·Ophthalmic Plastic and Reconstructive Surgery·Michael BaroodyJohn B Holds
Jul 2, 2003·Cancer·Scott T TagawaJeffrey S Weber
Dec 10, 2003·Expert Opinion on Emerging Drugs·L G Durrant, I Spendlove
May 1, 2010·Oncology Letters·Mays Al-ShaerChris Papageorgio
Mar 26, 2021·Science Advances·Maria Stella SassoMelody A Swartz